Observer variation in the diagnosis of superficial oesophageal adenocarcinoma

Background and aims: When to perform oesophagectomy for neoplastic progression in Barrett’s oesophagus is controversial. Some resect for high grade dysplasia whereas others defer treatment until intramucosal adenocarcinoma is diagnosed. Interobserver agreement for a diagnosis of high grade dysplasia or intramucosal adenocarcinoma remains unknown and may have therapeutic implications. Methods: Histological slides from 75 oesophagectomy specimens with high grade dysplasia or T1 adenocarcinoma were blindly reviewed by two gastrointestinal pathologists and one general surgical pathologist, and classified as high grade dysplasia, intramucosal adenocarcinoma, or submucosal adenocarcinoma. A subsequent re-review of all 75 cases by the same observers following establishment of uniform histological criteria was undertaken. Interobserver agreement was determined by kappa statistics. Coefficients <0.21, 0.21–0.40, 0.41–0.60, 0.61–0.80, and >0.80 were considered poor, fair, moderate, good, and very good agreement, respectively. Results: Interobserver agreement among all pathologists and between gastrointestinal pathologists when comparing high grade dysplasia with intramucosal adenocarcinoma was only fair (k=0.42; 0.56, respectively) and did not substantially improve on subsequent re-evaluation following establishment of uniform histological criteria (K=0.50; 0.61, respectively). Conclusions: When evaluating resection specimens and after implementation of uniform histological criteria, even experienced gastrointestinal pathologists frequently disagree on a diagnosis of high grade dysplasia versus intramucosal adenocarcinoma. Treatment strategies based on the histological distinction of high grade dysplasia from intramucosal adenocarcinoma using limited biopsy specimens should be re-evaluated.

[1]  M. Koike,et al.  Histopathologic characteristics of early stage esophageal carcinoma: A comparative study with gastric carcinoma , 2010, Cancer.

[2]  Patricia L. Blount,et al.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.

[3]  Tarun Mullick Telomerase upregulation in Barrett’s esophagus precedes the development of esophageal adenocarcinoma , 2001 .

[4]  M F Dixon,et al.  The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.

[5]  C. Hsieh,et al.  Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus--a longitudinal study. , 1999, Zeitschrift fur Gastroenterologie.

[6]  J. Goldblum,et al.  Jumbo biopsy forceps protocol still misses unsuspected cancer in Barrett's esophagus with high-grade dysplasia. , 1999, Gastrointestinal endoscopy.

[7]  Edward L. Lee,et al.  In situ hybridization for the detection of telomerase RNA in the progression from barrett's esophagus to esophageal adenocarcinoma , 1998, Cancer.

[8]  E. Kuipers,et al.  Epithelial Cell Proliferative Activity of Barrett's Esophagus (Methodology and Correlation with Traditional Cancer Risk Markers) , 1998, Digestive Diseases and Sciences.

[9]  M. Younes,et al.  p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia , 1997, Digestive Diseases and Sciences.

[10]  A. Cameron,et al.  Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. , 1997, The American journal of gastroenterology.

[11]  C. Moskaluk,et al.  p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. , 1996, Human pathology.

[12]  R. Heitmiller,et al.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. , 1996, Annals of surgery.

[13]  A. Neugut,et al.  Increased expression of the cyclin D1 gene in Barrett's esophagus. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  J. Richardson,et al.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. , 1996, Annals of surgery.

[15]  G. Tytgat,et al.  The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. , 1995, Surgical oncology.

[16]  F. Bosman,et al.  Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus , 1995, The Journal of pathology.

[17]  T. Rice,et al.  Surgical management of high-grade dysplasia in Barrett's esophagus. , 1993, The American journal of gastroenterology.

[18]  S. Li,et al.  What is the Ideal Treatment for Early Esophageal Cancer? , 1993, Endoscopy.

[19]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[20]  K. Sugimachi,et al.  Long-term results of esophagectomy for early esophageal carcinoma. , 1993, Hepato-gastroenterology.

[21]  W. Hop,et al.  Outcome of surgical treatment of adenocarcinoma in Barrett's oesophagus. , 1992, Gut.

[22]  P. Pairolero,et al.  Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? , 1992, The Annals of thoracic surgery.

[23]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[24]  B. Gayet,et al.  Superficial Squamous Cell Carcinoma of the Esophagus: A Report of 76 Cases and Review of the Literature , 1989, The American journal of surgical pathology.

[25]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[26]  R. R. Smith,et al.  The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus. , 1987, American journal of clinical pathology.

[27]  R. Lee Dysplasia in Barrett's esophagus: A clinicopathologic study of six patients , 1985, The American journal of surgical pathology.

[28]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[29]  D. Skinner,et al.  Barrett's Esophagus: Comparison of Benign and Malignant Cases , 1983, Annals of surgery.

[30]  Jacob Cohen A Coefficient of Agreement for Nominal Scales , 1960 .

[31]  D. Skinner,et al.  Dysplasia in Barrett's esophagus , 2004, Journal of Cancer Research and Clinical Oncology.

[32]  S. Semba,et al.  Expression of cyclin D1, CDK4 and p27KIP1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines. , 1996, Journal of experimental therapeutics & oncology.

[33]  N. Altorki,et al.  High-grade dysplasia in the columnar-lined esophagus. , 1991, American journal of surgery.

[34]  B. Reid,et al.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. , 1988, Gastroenterology.